[BidClub_]
Latent Space · · 51 min

Mini Brains, Beating Heart Organoids, and the AI That Predicts Them — Fabian Theis, Helmholtz Munich

Fabian Theis

BiotechAI & SoftwareTechnicalCompany Building
YouTube ↗
TL;DR
  • The virtual-cell opportunity is widening as perturbation data catches up with cell measurements. Theis points to ten million transcriptomes measured in one experiment and increasingly broad drug and CRISPR screens; RJ cites Biohub’s announced $1.8 billion collaboration. The virtual-cell question, in Theis’s framing, is predicting cell behavior under all kinds of perturbations. He cautions that equating a virtual cell with perturbation prediction is too simplistic: the ambition includes a cell’s input-output behavior, memory and molecular levels beyond RNA. Pharma needs cell-type-specific screens it cannot yet run at scale.
  • Organoids expand the opportunity into multicellular systems, while adding unresolved modeling problems. Theis’s example is “beating little heart cell clumps in a dish”: interactions emerge that a single cell line cannot capture. Missing immune components, limited data and unsettled representations of cellular neighborhoods keep this a research frontier.
  • Model complexity needs to earn its place against simple baselines and meaningful metrics. Logistic regression remains competitive for within-organ cell typing, while noisy drug-response prediction can struggle to beat the mean. Theis says ARC’s challenge also exposed exploitable metrics; his instruction is “Do your baselines properly,” then demonstrate value on harder questions.
  • Learning a cell’s state and predicting an intervention’s effect are separate modeling jobs. Theis describes a contrastive representation effort that reached 350 million cells across 16 species, with perhaps 100 million parameters. Perturbation prediction adds “the state X plus the action,” using a generative model such as CellFlow rather than assuming representation learning alone solves the problem.
  • Unique experimental data offers a clearer commercial moat than a virtual-cell model alone. Theis has repeatedly seen platform companies pivot to “We make a drug,” although the hosts point to emerging structural-biology and reinforcement-learning businesses following other paths. His Cancer Organoid Perturbation Atlas illustrates another buyer proposition: pharma pays for early access to distinctive experimental datasets.
  • Europe’s financing weakness appears at company scaling, in Theis’s account, rather than initial formation. Early venture funding and nondilutive support exist, but larger Series A and B rounds often pull companies toward US investors. His Helmholtz center supplies substantial research capacity—around 45 group leaders and 500–600 people—while he pushes each group toward at least one spinout within three years.
  • Experiment selection is becoming practical, while biological reinforcement learning remains an ambition. Lab Compass works backward from a desired cellular state to proposed interventions; Theis describes three or four experimental feedback cycles with a Cambridge hematopoiesis collaborator. The aspiration is “we want to RL everything.” RJ characterizes current approaches as “maybe active learning,” a description Theis affirms.
Digest · the substance, structured for research

1. Perturbation data makes virtual cells a more actionable proposition

  • RJ opens with Biohub’s announced $1.8 billion collaboration with DOE, NIH, Meta and Google to generate open, multiscale biological data. Theis connects that effort to the Human Cell Atlas, while qualifying his perspective: “my perspective is quite academic.” His expectation is that generative modeling and experimental feedback, already progressing at the molecular level, can increasingly move up to cells.
  • The basic measurement is a transcriptome: roughly 20,000 dimensions recording messenger-RNA counts in a cell, with many zeros. Latent representations compress that space; clusters suggest cell types, while trajectories can describe differentiation. Brandon’s analogy makes the distinction accessible: DNA supplies ingredients, and “each cell is its own sort of meal or dish,” whose composition transcriptomics attempts to recover.
  • What changed is coverage of interventions, not simply the number of observed cells. Theis recalls ten million transcriptomes measured in a single experiment, alongside screens extending to roughly 100 cell lines or batteries of 1,000 drugs. Previously, enormous cell collections often sampled a narrow perturbation space—perhaps control versus disease. Richer intervention coverage creates substantially more demanding prediction problems.
  • A perturbation is broader than a CRISPR knockout: neighboring-cell signals, hormones, media conditions, subtle genetic changes and combinations all belong in the input space. Knockouts are useful but unusually drastic. Theis hopes models eventually incorporate human genetics as perturbations; the practical need is pharma’s inability to screen broadly while remaining “cell type context specific.”
  • Theis cautions that a virtual cell is not simply synonymous with perturbation prediction. He describes the deeper ambition as modeling the cell’s input-output behavior, memory and different molecular levels—not just RNA. He calls equating virtual cells with perturbation-prediction models somewhat simplistic.

2. Multicellular context makes organoids compelling and difficult

  • For Theis, organoids demonstrate why researchers need to move beyond isolated cell lines. Cells can organize into small systems with emergent behavior: his example is “beating little heart cell clumps in a dish.” Such systems offer richer experimental readouts because cells connect and communicate, rather than merely supplying more observations of one cell type under another treatment.
  • Access to otherwise scarce tissue is another attraction. Theis describes taking skin cells, differentiating them into small brain-like systems to potentially study neurodegenerative disease genetics. He immediately keeps the limitations attached: organoids can lack immune components and adequate feeding arrangements. They reproduce useful pieces of organs, with substantial gaps.
  • How to represent these systems remains unsettled. Cell types provide a useful human categorization—“nature doesn’t care about” those labels—but local cellular niches lack an equally established vocabulary. Spatial omics and pathology therefore raise both conceptual and computational questions. Current models often treat organoids as distributions of cells; graphs might capture subtler relationships, but Theis says there is no agreed optimal representation.

3. Simple baselines survive until the biological question gets harder

  • On the hosts’ inductive-bias challenge, Theis argues that imposing priors too strongly can sacrifice predictive power. Perturbation data is nevertheless still limited enough that hybrid models “might be still the thing to go for.” His AlphaFold example is the shift toward learning rotational symmetry from data; longer term, he expects that “data beats human-made additional concepts in these models.”
  • His 2019 scGen combined nonlinear encoding with linear shifts in latent space, and simple alternatives remain formidable. For within-organ cell typing, logistic regression tools such as CellTypist remain close to the state of the art. Cross-organ classification introduces subtler tissue-dependent differences; his scTab work found gains from nonlinearity there. The biological question determines whether additional complexity actually contributes.
  • On ARC’s Virtual Cell Challenge, Theis says fixed metrics could be exploited; in his account, he thinks the model eventually crowned the winner was essentially based on flow matching. He says that, setting aside exploitation, the actual winner incorporated nonlinearities. RJ adds that a Bo Wang Nature paper traced some apparent linear-model victories to metric choice. Theis’s Open Problems approach asks participants to submit additional metrics, making the definition of success itself part of the scientific work.
  • Drug-response prediction supplies the sobering baseline: sometimes the challenge is simply beating the mean because measurements are so noisy. Theis’s instruction to students is “Guys—I mean, guys and girls—I know you want to do the fanciest deep learning thing, but please have the baseline.”

4. A useful virtual cell needs both representations and action dynamics

  • Nicheformer illustrates a harder task than assigning a cell label: can one cell’s expression state predict its neighbors’ expression? Communication leaves traces of the surroundings in the measured cell. Theis says stronger nonlinear models become useful when researchers ask for this subtler information. Whether existing data contains untapped signal therefore depends on the question posed, rather than a blanket verdict about foundation models.
  • Training objectives remain open territory. The field has borrowed masked-autoencoder approaches from language modeling, while exploring tabular foundation models, JEPA-style methods and contrastive learning. Theis says early biological foundation-model papers often failed to demonstrate scaling laws. Reviewers should require evidence that complexity delivers improving performance across increasing examples and samples, rather than accepting model size as its own justification.
  • His contrastive representation work compared against Geneformer at around 30 million cells; the version on Hugging Face reaches 350 million cells, with perhaps 100 million parameters. That larger latent space spans 16 species, potentially supporting cross-species and cross-tissue comparisons. Evolutionary questions become conceivable, although Theis explicitly says they are not his group’s core expertise.
  • Intervention prediction adds dynamics to those representations: the model takes a state and an action, then predicts the next state. “I would not claim that pure representation learning is the right way to go,” Theis says of perturbations. His group adds a generative push-forward model using flow matching; he says CellFlow, accepted at Nature Methods, improves perturbation generation but depends heavily on a good latent space.

5. Germany’s research capacity meets a financing and data-access constraint

  • Helmholtz’s federal funding supports sustained research programs rather than university-style undergraduate teaching. Theis describes his Computational Health Center as roughly 45 group leaders and professors, with perhaps 500–600 people spanning cellular modeling, DNA, protein design and patient cohorts. He thinks it is Europe’s largest academic center for health AI research. University and clinic affiliations supply training and translational connections; bringing these scales together supports a broader “virtual human” ambition.
  • Against a host’s concern about German startup bureaucracy, Theis argues that formation is increasingly competitive, especially in Munich and Berlin. He says the EU creates just as many startups as the US. His diagnosis is that Europe drops off when companies scale: early venture and nondilutive funding exist, but investors taking larger risks are less available. He has repeatedly seen companies seek US funding for larger Series A and B rounds, while acknowledging that this simplifies the picture.
  • Health-data integration remains another friction. Theis cites Finland’s FinnGen and Denmark as examples where population sampling and medical records are connected better than elsewhere; in Germany and the US, fragmented records make patient trajectories difficult to build. He points to the European Health Data Space as a mechanism for cross-border combinations, where “maybe in the next 2 years, these things need to start working across borders.” The vision is developing, he says, but implementation is slower than desired.

6. Platform companies still need a buyer and a defensible data advantage

  • Theis’s commercialization warning starts with companies promising “We decode biology” without specifying what customers will buy. Platforms are attractive, but consulting does not automatically become a scalable business. He has watched many virtual-cell companies eventually announce “We make a drug,” because investors understand funding an identifiable therapeutic asset more readily than an open-ended modeling platform.
  • The hosts push back with a changing market: structural-biology businesses, including Chai, and companies selling reinforcement-learning environments suggest alternatives to owning drug pipelines. They would like comparable activity around systems biology. Theis does not dismiss that possibility; he redirects attention to what those businesses can uniquely generate and provide.
  • His example is the Cancer Organoid Perturbation Atlas, a consortium built with multiple pharma partners. Companies buy in because they want early access to perturbation datasets. Coupling modeling to distinctive experimental production is where he sees the “sweet spot”: the model comes with information customers cannot readily obtain elsewhere, giving pharma a concrete reason to participate.
  • Theis also questions how many standalone AI platforms the market can sustain. He raises the possibility that “Astra 2.0” might eventually perform parts of the work, adding pressure to differentiate beyond the model.

7. Dual supervision turns biological ambiguity into computable questions

  • The Munich School for Data Science embeds a methods supervisor and a domain supervisor in a “Y” structure. Students attend both lab meetings, learning biological or medical language while developing computational methods. Theis’s point is that important domain problems often arrive incompletely formulated; a quantitatively trained student can turn that ambiguity into a metric, a model and a research project.
  • After roughly eight years, he sees graduates becoming both capable analysts and model builders, with destinations spanning pharma, research, startups and pure AI. NVIDIA hired two of his people in one month a few months before the conversation. Their advantage, he argues, includes having helped define a difficult real application, beyond demonstrating a small benchmark improvement.
  • The approach now spans spatial measurements and single-cell proteomics alongside RNA; Theis mentions a Science proteomics paper from the previous year. Commercial translation is becoming explicit, too: he has asked every group leader to aim for at least one spinout within three years, while saying students increasingly push toward startups themselves.

8. Lab Compass moves the model into repeated experimental decisions

  • Theis’s progression is “from mapping, we went to prediction,” followed by steering the next experiment. Conventional academic projects often stop at a model, a concept figure and limited validation before moving on. Repeated feedback would make learning more continuous, but he cautions that genuinely running multiple computation–experiment loops remains uncommon, even where organizations promote the idea.
  • Lab Compass addresses the inverse problem: given a forward model and a desired cellular state, what intervention should produce it? Theis describes an inverse generative model intended to answer that question. At the time of recording, he expected the work on bioRxiv “today or tomorrow”; selecting an optimal next experiment, he emphasizes, is itself a difficult modeling problem.
  • With a Cambridge collaborator working on hematopoiesis, the group established three or four experimental loops that iteratively improved a model. The enabling factor was a relatively rapid experimental system, alongside close collaboration. Persuading experimentalists to spend substantial time on an unfamiliar model-recommended intervention remains difficult; biological intuition can pull the team toward compromises instead of following the proposed experiment.
  • Robotics may eventually help, but Theis thinks it is a little early while assay cycles remain long. “We want to RL everything” expresses the destination, which he calls “a bit out there.” RJ characterizes present approaches as “At the moment it’s more maybe active learning,” and Theis affirms that characterization.
Full transcript
Fabian Theis

We can really start guiding experimentation now. Before, we built these human cell atlases, which had this mapping aspect. Then we talked about the world-model prediction problem. We went from mapping to prediction, but now we can actually steer the next experiment.

Quite frankly, very often the papers ended with some model, maybe a concept figure and a little bit of validation. Then you typically start the next project. Of course, you learn a bit, but it’s not continual learning. A new thing we call Lab Compass is an inverse generative model that allows you, once you have a forward world model or whatever, to figure out what you need to do to reach a certain state. Obviously, the ultimate vision is that we want to use RL for everything, including this loop. It’s a bit out there, but I think we’re slowly getting there.

Speaker 1

Welcome to the Latent Space AI for Science podcast. I'm RJ Hanocki, CTO of Mira Omics. I'm joined by my co-host, Brandon Anderson, who develops RNA therapeutics at Atomic AI.

I can’t emphasize enough how much Fabian Theis and his labs and companies have contributed to the development of systems biology and the various iterations of the virtual cell concept. Papers and models come out of his lab faster than I can read them, and the lab is consistently moving the ball forward on our understanding of how to observe and model the behaviors and interactions of cells. Just as importantly, his work often focuses on creating tools that researchers and scientists actually use in their day-to-day work.

Most computational biologists have probably used Scanpy and AnnData at some point. This work has led to the creation of scverse, an amazing collection of open tools that has attracted many contributors. Fabian is one of those academics with more honors than you can possibly list, but suffice it to say that he leads many of the AI and computational biology efforts at Helmholtz Munich and related institutions, and participates in many other industry efforts.

Fabian, it’s really great to meet you. Thanks a lot for joining us.

Fabian Theis

Thanks for having me. I’m really looking forward to the discussion, man.

1. Why Virtual Cells Are Rising

Speaker 1

I’ve been tracking your work for a long time, so it’s a great honor to finally get you on the show and talk to you. Let’s kick things off with some of the hype happening right now. There’s a ton of interest in structural biology. Anthropic and OpenAI’s biopharma initiatives focus heavily on designing molecules.

On the other hand, virtual cell and systems biology approaches really haven’t gotten as much attention recently. Maybe Zera and Noetic are good counterexamples there. But Biohub just announced a $1.8 billion collaboration with the DOE, the NIH, Meta, and Google to collect and open-source multiscale biological data that can be used to develop a new generation of virtual cells. Do you think we’re about to see renewed interest from the pharma industry in virtual cells, based on the activity we’re seeing in academia right now?

Fabian Theis

I should disclose before I answer that my perspective is quite academic. When I talk to my friends and colleagues who sit in the startups day by day, they have the overview and intuition I have about what different research labs are doing, but for the startups. They know which things are hot and what investments are happening. I don’t really have that kind of overview.

Having said that, you mentioned Biohub’s initiative, which is also heavily coupled to the Human Cell Atlas, an international, worldwide consortium pushing the next level of dataset generation. I do think there are a whole bunch of reasons why we’re going to see these models scale up. They’re working well as generative models, and lab-in-the-loop approaches at the molecule level are now being exported to work one level up, at the cell level.

I think the first reason, and maybe the most important one, is the data generation, which you really hit on. We’ve had the concept of a virtual cell for a while. My lab started perturbation prediction modeling and using machine learning in 2019, with a paper we called SEGen at the time. It was a nonlinear model, but essentially did a linear transformation in latent space, and it was actually quite good. Even nowadays, many of these pseudo-linear approaches are still doing a good job. But I think the datasets and the questions we asked were still on the simplistic side. That’s why it didn’t take off yet.

When people talk about virtual cells, I think what you’re actually asking is: Can you predict how a cell would behave under all kinds of perturbations? That’s a deep question. If you really think about it, it’s maybe even a holy grail in computational biology or systems biology: this input-output system that is a cell, with memory, all its specifications, and all the different levels of molecules—not just RNA.

Being able to map this out raises the question of what understanding even means. That’s a bit of a meta-problem, but I think you understand or model a system very well when you can predict its output behavior given different inputs. This is why people nowadays often equate a virtual cell with perturbation prediction. I think that’s a bit too simplistic, but these perturbation-prediction models—maybe what you mean by a virtual cell—are taking off a lot.

The startup landscape is exploding there. We talk a lot about Europe, but in the Chinese ecosystem, too, there are many additional efforts happening now. I hope this isn’t just a kindling of the flame because everyone is adding AI to their work, but because pharma desperately needs to be cell-type-specific in its screens, which it can’t yet do at that scale.

2. Perturbations At Scale

Speaker 2

Maybe you could expound a little bit on what perturbations unlock. We talked to Zera recently, and they’re doing these perturbation screens. What do you think the next generation of data is going to unlock in addition to that?

Fabian Theis

For me, if I may—stop me if I get too much into these old stories. I’ve been trained as a machine learning scientist for the longest time, doing all kinds of things. I started with single-cell early on, using qPCR. To be honest, initially it wasn’t so much because biology was what I was interested in, but because we had high sample numbers for that. Even early on, it was clear that the number of qPCRs at scale—and then, of course, transcriptomes—was getting really big.

When I started my career, we had a few bulk RNA-seq samples. Now we had thousands of them. But now we’re entering a new regime. One of these eye-opening moments was when Parse Biosciences had the—I think they call it the GigaLab or something like that. There are similar ones from competing companies now. They measured 10 million transcriptomes in a single experiment. I thought that was next-level stuff.

The step from just getting more PBMCs as a control to actually doing something to them at scale gives us the cell space, but then there’s the perturbation space, which was typically very scarce. It was often just control versus disease. The number of points you had in the perturbation space was much smaller than the number of cell observations. But now this is exploding. You might have 100 different cell lines where you do full perturbations, like full CRISPR knockout screens, or batteries of 1,000 drugs added, and suddenly that space gets really rich. Then you can start doing all these fancy perturbation-prediction things. It’s crazy how quickly the scale is increasing.

We’re involved in a whole bunch of things where we go beyond cell lines and do organoid perturbations. Maybe if we have time, we can talk more about that. I’m quite convinced we need to go to multicellular systems to get really interesting readouts. Everyone is scaling these levels up, and at some point, we may even go to human genetics as a perturbation.

Speaker 1

Can you just explain what a perturbation is, for people who aren’t familiar?

Speaker 2

Actually, would you mind backing up one step more than that? What do we even mean by measuring transcriptomics? You were talking about PCR-based approaches and perturbations.

Fabian Theis

When I give public talks, I typically say: We have the genome for the body from the Human Genome Project, but it’s pretty much the same everywhere. So why do we have all these different cell types? What’s happening specifically? One of the first levels is that different things are read off the genome in each cell. These messenger RNAs, which encode the various downstream proteins, are expressed differently in different cells.

In a human, maybe there are something like 20,000 different genes, with many, many more transcripts produced through splicing. But that’s the rough level. What you de facto have is a 20,000-dimensional vector for each cell, with a whole bunch of zeros where something isn’t present and a whole bunch of numbers representing how many messenger RNA transcripts you have. These are called transcripts, and this is called the transcriptome.

You then have this 20,000-dimensional space that we often encode in a nicer latent space, with a submanifold where the actual cell cloud lives. Each point in the cell cloud is one cell. If these 20,000-dimensional vectors cluster together, we call those clusters cell types. If they form a sausage-like shape, we call them trajectories, like cell differentiation: a fertilized egg cell giving rise to all the cell types in the body.

Speaker 1

DNA is sort of like a recipe book, or maybe it’s a bunch of genes or ingredients. Each cell is its own meal or dish, a combination of different ingredients. Transcriptomics is figuring out what ingredients went into making each meal. Is that a dumb analogy?

Fabian Theis

I have a bunch of foodies as kids, so I’ll use this metaphor a bit more often. I like it. Thanks, Brandon. I love it.

Speaker 1

And perturbations are when you somehow perturb the genome or transcriptome so that it has different transcripts in it. Typically, that’s done with a CRISPR knockout, where you remove a gene from the genome, which causes it not to express that gene. Then you see what phenotypic changes, or actual changes in the physical biology, occur because of the perturbation. Is that more or less right?

Fabian Theis

Maybe I can take a step back there, because I think you’re fully right, but that’s one of the hardcore types of perturbation. Fully knocking out a gene happens a bit in evolution, but most things are a bit more subtle. Of course, in order to understand the system, it’s a good idea to take out bits and pieces.

In normal development, or when we’re in homeostasis, cells talk to each other all the time. They live in these complex multicellular states, with all kinds of communication happening between cells. They’re always receiving things from outside and responding to them. For me, a perturbation space is really just an input space of things that happen to a cell, maybe because it’s next to another cell and there’s some signaling happening, or some gradient or hormones coming in.

You can’t tune all of that up or down. Even something as basic as the different media conditions used when pharmaceutical companies do drug screens in vitro can have a huge impact. It’s still a bit like bio-driven alchemy, figuring out what cocktails to use to take skin cells and turn them into more or less embryo-like cells, so that you can make new cells to heal different things in your body. These are what are called Yamanaka factors, for example—Nobel laureate-type work.

I think a space of perturbations—things you can do to a cell—can be very rich. It can include changes in a gene, like a full knockout, or something more subtle, like human genetics. We need to put all of that into a big space of things we can do that have an influence on cell state. A virtual cell model should take all of it, including combinations, disease, time, and whatever else impacts the cell.

3. Organoids Reveal Cell Context

Speaker 1

That’s a great connection to the idea of organoids. Can you talk a little bit about what an organoid is, how it connects to this concept of perturbation space, and what you do to it in addition to adjusting its context?

Fabian Theis

When I first learned about this concept—I’m not a trained biologist, so I typically learn about things by reading a bit or talking to colleagues and friends—I was super impressed that people could take cells out of a body, from a cancer or whatever, and let them grow into small multicellular systems that start connecting and doing things.

People can take some cells, put them in a dish, and grow little mini-brains: a set of neurons that start connecting and talking to each other. People have shown that these mini-brains in a dish can compute. Similarly, people can grow heart cells into little heart organoids. We have a bunch of local collaborations with fantastic partners, and those organoids actually start beating. You have little clumps of heart cells beating in a dish.

There are simpler systems, too, like the colon, where this works very well, and there are a whole bunch of cancer systems. Organoids can also help study diseases when material is hard to acquire. If you want to look into the genetics of a neurodegenerative disease, it’s typically very hard to get access to tissue. So you can take cells from the skin, differentiate them, and turn them into these mini-brains, then potentially study some things there.

Replicating little bits of organs in a dish—that’s why they’re called organoids—is fascinating. There are all kinds of limitations, obviously. Often the immune system is missing, and maybe they aren’t being fed properly. There are all kinds of problems, but it’s much more than just a cell line, which is one cell type.

Speaker 1

Moving to the modeling side, how do you model that?

Fabian Theis

That’s a bit of a research frontier. I don’t think people have agreed on the optimal way to model it, particularly because there isn’t as much data as one would like. RJ, you’re involved, if I understand correctly, in a whole bunch of spatial omics and H&E pathology efforts. There are so many samples available for pathology, and now we’re increasingly doing more spatial omics. I think people are less clear about how to represent spatially connected datasets and then break them down at the organoid level, compared with dissociated cells.

Taking this a bit simpler, if we look at the space of dissociated cells and the groups within it, we have this beautiful metaphor of what we humans call a cell type. Nature doesn’t care about that; it’s just us putting categories on top of things to help us understand the complexity. I don’t think we have a similar metaphor for local niches of cells. Maybe a little bit, but in H&E, whenever I talk with pathologists and see what they do, it’s often very qualitative and maybe not at that level yet.

I think we need to develop a categorization language for ourselves. Maybe computationally we don’t need it as much, but we also need to think about how we deal with this. At the moment, we essentially deal with it as distributions of cells. That’s the solution for now, but it could be much more subtle, like graphs or something.

4. Balancing Bias And Data

Speaker 1

On the one hand, you have the bitter lesson: you remove inductive bias, and you can use a larger dataset that applies to your problem. That helps you get more accurate models because your distribution is wider, or whatever. But there’s a countervailing tendency, maybe the flip side of the bitter lesson. In data-poor regimes, you have to introduce a lot of inductive bias to get enough statistical power to make good inferences.

There’s also a second side to that, which John Platt brought up in our discussion with him not too long ago: you have predictive models and descriptive models. What you really want as a scientist is to arrive at a simplification, a descriptive model, where you can say, “I’ve tested all the apples, and gravity works in this way on apples.” Then I’m modeling it as a universal concept so we know it works on planets as well.

I want to understand what simplifications, insights, or actual mathematical or scientific models are becoming apparent that will help reduce all this complexity, so we can gain meaningful understanding from these really large datasets.

Fabian Theis

That’s a very important and, I think, kind of deep point. It breaks the field into maybe two different groups of people with answers. How much inductive bias, or priors, do we need to put into a model to make it more explainable, and potentially more robust when going out of distribution? Or how much are we just going to rely on bigger data to make the model more expressive?

I need to be very clear before we go into the philosophy.

I think the literature has clearly shown over decades, at least for many of our main datasets, that if we build in a priori inductive biases too strongly, we might lose predictive power. So it comes at a cost. If you’re a physician—or even a patient, perhaps, if you might have cancer or not—you may want the best model as a predictor. If you’re getting treated, you might want a model that’s a bit less good but that you understand a bit better. But for prediction, at least, I think you want the best. And I don’t think that’s entirely clear.

In our field, the cell scale is big, I think, but the perturbation-space scale—the things we do to the cells—isn’t as big. I don’t think we’re yet in a super data-rich regime, so in our case, these hybrid models might still be the way to go. But more and more, of course, and this is the honest lesson from large-scale machine learning, is that at some point data beats human-made additional concepts in models. One simple example I often point to is AlphaFold. The first models made an extraordinary effort to make molecules rotationally equivariant. They built that into the learning process. In later versions, rotation symmetry was automatically found by the model with more data, and the model was a bit more flexible. Whatever physical constraint you put in isn’t always as rigid, so you gain something if you let the model learn from the data. I think in the future, the larger share of the more widely used models will be these more flexible, data-based ones, with interpretation added on top afterward.

Speaker 1

This also brings up a question for me. You recently wrote or co-authored a paper on the statistical power of current-generation virtual cells, in terms of the lift you get from additional data in those models. I think you said that the objective function or training methodology might be the problem, and not necessarily that the information isn’t in the data. Can you explain that a little, and why you think there might be plenty of untapped information in the data? Where does that get us, and what do we need to do to go further?

Fabian Theis

I think it’s fair to say that early on, we had very small, limited prediction models, learning latent spaces first and then perturbations on top. When large-scale foundation-model representations came out, everyone bought into the hype, perhaps a bit too much. Then comes the sobering-up phase, or something like that.

Speaker 1

Yeah.

Fabian Theis

There were a whole bunch of papers saying, “Hey, maybe even a more or less linear model does a good job.” Our scGen paper had some of these benchmarks early on, showing that it’s not such an easy task to improve on that. I think there’s some truth to it: with the current state of the data, for some things, like predicting the effect of a CRISPR perturbation in a cell line, you might not need the fanciest model. If you want to predict a cell type, logistic regression is mostly fine.

But if you want to predict something more difficult, for example, in our Nicheformer paper, which is a foundation model for spatial omics, we introduced a new task. You have the gene expression, the state—the latent space—of a single cell. Can you predict the gene-expression state of its neighboring cells? They’re always in communication; they talk to each other, so you can see a remnant of one cell’s state in the other. That’s harder to do. For these harder tasks, you need stronger, more nonlinear models, and you need to look for more subtle information in the data. Whether you can find more information-rich features depends very much on what you ask.

In the self-supervised learning phase, we’re definitely not yet at the best way to represent and learn these things. There’s a lot of copying from NLP and LLMs, like masked autoencoders. People are still debating the typical approach and the types of losses and representations to use, perhaps because this is often tabular data. People are trying tabular foundation models, and there are a lot of JEPA-type approaches. We have one approach where we use contrastive learning, so people are playing around with the losses and the representations.

I think reviewers nowadays are looking much more closely—and I’ve been advocating this for a long time—to make sure you properly show scaling laws. That was missing from the early foundation-model papers. People hadn’t really shown that you need this complexity to scale up. But if you can really demonstrate scaling behavior across examples and samples, then I think you get buy-in for these models. There aren’t as many inductive biases in these approaches, so I do think we’re going to hit this regime quite soon. We’re already seeing it in a few papers. For example, in our contrastive-learning paper, scConcert, we show quite strong scaling behavior. In the paper, we went up to maybe 30 million cells, comparing with Geneformer. On Hugging Face, we now have a 350-million-cell model, with maybe up to 100 million parameters. We’re really going to a large scale, and we’re already seeing nice scaling behavior starting to emerge.

Speaker 1

Just to be clear, at 100 million parameters and—did you say 300 million cells?—you get a lift in what kinds of applications? Are these the Nicheformer kinds of questions, where you’re asking, “What is my environment based on my transcriptome?”

Fabian Theis

Yeah. I mean, the ultimate thing we want to do is predict perturbations better, because that’s what people nowadays understand by a virtual cell. For that, I wouldn’t claim that pure representation learning is the right way to go. Sorry to repeat the subtlety, but typically you learn the state space with these foundation models. The way the model behaves under an action, under a perturbation, is where you need more world-model-like approaches.

World model is the very hip term. I’m sure you’ve had this—

Speaker 1

Yeah.

Fabian Theis

—on your podcast already at some point. It’s been—

Speaker 1

Yes.

Fabian Theis

—all over machine-learning conferences in the last year. But a perturbation-prediction model, like a virtual cell, is effectively a world model in transcriptome or other omics space. It’s not just a model that is F of X, but F of X comma A: the state X plus the action, predicting the next state, X prime. For this, you might need other combinations. What we typically do is learn the representations with, for example, scConcert, and then put a generative model on top to model the push-forward along the action. For this, we use something like flow matching.

Our CellFlow paper has just been accepted for Nature Methods, and we show that these approaches are much better at generating the effects of perturbations. But they depend very much on a good latent space. For this, using the scConcert latent space, we went to 350 million cells and included multiple species. You now have 16 different species where you can potentially look for similarities. Suddenly, you can ask evolutionary questions that you couldn’t before. Not that we can do this particularly well—it’s not our core expertise—but you can start doing these cross-species, cross-tissue latent spaces.

5. Linear Models Set The Baseline

Speaker 1

I’m curious about the history of some of these different models. You just gave us a rapid version of it. One thing that was somewhat famous in the community was the point about linear models. Can you explain specifically what the key point was? This is one of those things in classic machine learning: make sure you understand your baselines well, or you can spend a lot of time spinning your wheels and fool yourself. I think there was a famous open competition through the Arc Institute that was a glass of cold water on everyone’s faces.

Speaker 1

Can you maybe give a little bit of history about that, why we thought this was exciting, and where this had us pivot a bit?

Fabian Theis

Yeah. It sounds like such an obvious lesson, right? Do your baselines properly. But in a field rushing toward the gold pot of the virtual cell, people maybe weren’t as careful with the baselines. There are a whole bunch of subtleties with respect to holdouts and so on that weren’t always fully observed, which is why some of these things happen.

One of the first observations was in something as basic as cell type prediction. Nothing super fancy: you give me a new transcriptome, and I tell you which cell type it’s from, maybe even which organ. Even nowadays, some models close to state of the art are really just logistic regression. For such a simple categorization, that’s actually not so bad. There’s CellTypist, for example, which does a good job. I think we had a paper maybe 5 or 6 years ago with the very plain title “Deep Learning Is Not Needed for Cell Type Prediction.”

That’s true if it’s within an organ. If you go across organs, it suddenly gets a bit more subtle because cell types recur in different organs, and immune cells change subtly depending on which tissue they’re in. Then you need to do a bit more. For us, there was a paper called scTab, a tabular foundation model, a predictive model of that type. We showed that this nonlinearity was really adding something beyond the baseline.

For perturbation models, which you were asking about, Brennan, early analyses, particularly of Perturb-seq, were done with classical linear models on pseudobulk. Around 2019, we had scGen, where we started introducing linear shifts in latent space, so they were nonlinearly encoded. We always compared them with simpler linear shifts. But as the field got more complex and datasets started appearing, people began asking more and more perturbation-related questions.

There were a whole bunch of early competitions, for example, one run by MIT. We’ve also been running a regular NeurIPS competition on prediction problems in single-cell data, sometimes for data integration and also for perturbation prediction. That was very well attended. The cherry on top was definitely the Arc competition, which called itself not just a perturbation prediction challenge, but the Virtual Cell Challenge. That just sounds a bit cooler, right? It was very well received, but the metrics were maybe robust and maybe not so easy to work with.

Our solution in the Open Problems consortium, where a lot of labs contributed, was that people should submit their own metrics as well, to quantify subtle things you might not have thought of before. The Arc competition fixed a bunch of metrics that weren’t even very single-cell-specific, and they could just be exploited. I think the winning model, which was eventually crowned the actual winner, was essentially based on flow matching. It was based on this idea of a flow, a CellFlow-type idea. That shows that some nonlinear approaches are needed in this case. If you remove the exploitation, the actual winner was something that incorporated nonlinearities.

Nowadays, we see that linear or additive models aren’t cutting it for more complex things. But even now, if you’re working with a simple setting, with a few cell lines and gene knockouts, then, particularly when the effects are subtle, these more complex models can overfit a bit. That’s why a linear baseline is always very good. I always tell my students, “Guys—I mean, guys and girls—I know you want to do the fanciest deep learning thing, but please have the baseline.”

For drugs, a baseline as simple as predicting the mean can be the hardest baseline—not even a linear model, just doing better than the mean. Sometimes that’s not as hard if there isn’t so much noise in the data, and this stuff is super noisy.

Speaker 1

I just wanted to add one point: Bo Wang and some of his collaborators just had a Nature paper on how the metric was actually the problem in some cases where linear baselines beat some of the models as well. So it’s clearly not only metric hacking; asking the wrong question leads to the wrong answer. Or it’s a choice of metric.

Fabian Theis

Yeah, I think you can discuss that. At some point, we’re going to have agents trying out all kinds of combinations of whatever algorithmic thing you can come up with. In fact, we have some collaborations with AutoML-type labs to try this out. Maybe what’s left sounds a bit too harsh, but maybe our biggest ideas go into this metric formulation, right?

Speaker 1

One thing I’ve been really interested in is the different models of funding in research academia. I think Germany has a fundamentally different structure from the US. How is your institution set up, and how does that give you distinct opportunities compared with a US-based research model?

Fabian Theis

I very much agree that these funding models matter for flexibility, but also for the teams you can set up and the long-term vision you can have. Helmholtz isn’t just in Germany; I would say it’s maybe Europe’s largest research organization in terms of funding. It has different areas of focus, with health being one of the big ones, but also materials, information sciences, physics, and so on. Essentially, it gets federal money to invest in deep research questions.

I’ve been building up what’s called the Computational Health Center at Helmholtz Munich, which I think now has maybe 45 group leaders and professors and 500 to 600 people. I think we’re the largest academic center for health AI research in Europe. We have people working at all scales. I’m focusing on the cellular scale, but there are people doing DNA foundation models, protein design, patient-cohort representation, genetics, and so on. Now you can start bringing those things together, and one of our big visions is to move toward the virtual human.

The key thing is that, in contrast to universities, even though we’re all affiliated with universities—mostly the Technical University or the University of Munich, interestingly, the 2 top-ranked universities in the European Union—we don’t have undergraduate teaching. We essentially just have PhD students and postdocs, but we interact a lot with the universities, and in particular with the clinics, because we want to have that translational component. This may be a bit similar to NIH-type models in the US, but distributed across the country, not just in one place.

One interesting link is that the government and this realization in Germany are increasingly showing that there needs to be a much stronger transfer component—not just translation through universities, but also value creation outside the academic realm, which obviously means more going into startups. The Boston environment has always been one of the key examples, but now, of course, so is the Bay Area. Recently, when I was visiting—maybe Genentech, or some colleagues—we went to a restaurant, and one of the waiters asked us, “Hey, are you guys talking about AI and bio? I’ve been interested, too.” Everyone is thinking about startup ideas, and I think our PhDs are doing that more and more. We’re learning, too. In terms of value creation, Munich in particular is now perhaps the prime place on the continent for VC capital, and deep tech, particularly bio and defense, is really exploding. So this stuff is starting to work.

Speaker 1

The thing you were talking about with startups is really fascinating. I’ve heard that Germany has had some issues with its startup ecosystem. It’s difficult to create a startup there compared with even other places in Europe. What’s the competitive landscape for startups in Germany right now, and how does Germany become more competitive broadly?

Fabian Theis

I have a vested interest in this because I’m probably going to get my German citizenship soon.

Speaker 1

Welcome. Let me know if you come by Munich.

Fabian Theis

Traditionally, Europe—and Germany in particular—has been quite bureaucratic, and processes are far less digital than you’d expect in other places. I’m not saying the U.S. is the best example of fully digitized processes, but things are definitely faster. People have realized that now, and I think startup creation and implementation in Germany are more than competitive compared with the rest of Europe. It’s actually one of the prime places, with hotspots such as Berlin and, in particular, Munich, which I think has the highest number of startups.

Even nowadays, if you look at the European Union, there are just as many startups being created as in the U.S. Where Europe, and Germany in particular, drops off is at the scaling part. There’s early-stage VC and non-dilutive funding, but when you get to scaling, the big VCs that take bigger risks aren’t nearly as present. I’ve seen this again and again: if you want to get into the bigger funding rounds, like Series A and Series B, people start going to the U.S. for that, too. Maybe I’m simplifying a bit, but that’s my current learning, Brennan.

Speaker 1

Okay. You’re on the board or, I guess, part of several local startups, right? What does it take to go from an idea to creating a new startup in Germany?

Fabian Theis

I don’t know if you’ve heard that the European Union tries to regulate a whole bunch of things, and that can sometimes be an advantage. It’s kind of cool that all across Europe we can use a mobile phone, and you may have heard that everyone needs to have USB-C for their mobile phones now. Some good things are coming. But, of course, things like the AI Act make things a bit more complicated.

Luckily, not yet for research, but data access across hospitals can be an issue. We were talking about health deep tech, right? There are some systems in Europe that I think are fantastic. I’m thinking about Finland, FinnGen, Denmark, and so on, where there’s a very detailed description of the population, including sampling, and medical records are connected far better than elsewhere.

The U.S. is also a similar mess to Germany when it comes to getting all the systems to talk to each other. When patients go to different states in the U.S., it’s similar to when they go to different places in Germany: it’s very hard to build patient trajectories. But there are places that know how to do this. The European Union has something called the European Health Data Space, where, maybe in the next 2 years, these things need to start working across borders. You need to start building these combined health records. I do think the visions are starting to happen, but the scale isn’t happening as quickly.

For a tech startup, what I’ve noticed is that the biggest thing is having the best team for it. We have professors and PIs who really think about this. For example, in my department, I said, “Guys, every PI, every group leader should expect to have at least 1 spin-off in the next 3 years. Let’s see how that works.” You need to get people a bit on that track, but I think this is happening from the bottom up nowadays anyway, with students actually pushing for it.

They realize there are a lot of opportunities at the moment, particularly with this computational angle being pushed even more to the forefront, so we can now start guiding experiments. We haven’t really talked about that much, but once you have these perturbation world models, you can go back and drive the experiments. I do think computational startups can be very good for data generation. This won’t just turn into nice papers, which is mostly all our business, but also into this next generation of startups. You see a few of these popping up, where you actually get the lab and the loop implemented.

Speaker 1

What do you see as some of the most promising areas for commercialization of virtual-cell-adjacent ideas?

Fabian Theis

It’s interesting. If you look at earlier examples—and of course, people always refer to what OpenAI, Anthropic, and so on wanted to do—they didn’t really know how to make money, and some people might argue they still don’t know nowadays. There are a few startups that got quite strong investment and said, “We build a foundation model of biology. We decode biology,” without actually saying what they wanted to do with it.

I’ve seen this again and again: these platform-type ideas are super attractive. They fit into what we know. You spoke about some of the tools and platforms we build, like Scanpy and scverse, right? But turning this into something that makes money is not as obvious. There might be some sort of consulting business, but when you say you’re building a virtual cell platform, what investors understand—maybe even more so in Europe’s more conservative VC ecosystem than in the U.S.—is that at some point you develop a drug, and then it’s clear.

I’ve seen so many of these platform companies pivot at some point to, “We make a drug.” On the side, of course, we have our virtual-cell business, but we have 2 drugs that we found, and if you put a lot of money in, maybe you have some other counting sums. A few companies are still sticking with scaling up the AI business, but it’s not as clear how you would turn this directly into a viable, scalable business model, or whether there’s even room for many of these. And, of course, there’s also this anxiety that at some point Astra 2.0 might be doing parts of this already anyway.

Speaker 1

Yeah. I think this has actually been a thesis of mine: until recently, every single company that builds a model ends up just building drugs, because that’s the path to monetization over time. Landing sales with pharma is very difficult, or you need some other big-pocket spender. If you’re a tools company and you say, “I’m going to build an asset, and then I can sell that off,” that’s really attractive to an investor.

Fabian Theis

Yes.

Speaker 1

But we’ve seen the opposite happening this year, right? You have a couple in structural biology, you have Boltz, and Brandon will know them better, but there are a couple of those. Chai is one that we talked to, and we’ve interviewed a few that are doing reinforcement-learning environment plays as well. I’d love to see the activity level in structure that we see in Structural also doing things like what Noetic is doing.

Fabian Theis

I think Noetic is a good example in the sense that they also have a nice scale of data generation, and a big part of that is access to data. We talked before about these organoid perturbation-type things. We’ve actually been setting up a consortium in collaboration with a whole bunch of pharma companies, which we call the Cancer Organoid Perturbation Atlas. Pharma buys in because they want early access to some of these perturbation datasets, right? I think some of these deals go in that direction.

If you couple it with data generation, not just the modeling part, I think that’s where the sweet spot is, where pharma actually buys in. More and more of the companies I see are building their moat not just around a virtual cell model, but in combination with unique, specific data. That’s also more value creation.

Speaker 1

I don’t know if this is exactly correct, but I read that you said somewhere that you have your students follow what I think you called a Y model, in which you have to have a methods and a wet-lab advisor. That sounds super interesting and super relevant to our conversation right now about data being so important, and all the attention on lab work and that being a moat for a lot of companies. Can you talk a little bit about that?

Fabian Theis

Thanks for raising this. I’ve been setting up what’s since become quite a big thing, called the Munich School for Data Science. This is beyond biology; we had a whole bunch of other disciplines. There, we had this supervisor model where 2 PIs always needed to come together to make a proposal and propose it to the students in a graduate-student-type model, which has this Y shape. There’s a methods-oriented one and a domain one, right? And then there’s a supervisor and a student.

Sometimes we had 2 students under the Y model, so Y plus Y equals H. You get it? I think this idea is somewhat trivial nowadays, but I thought it was good to bake it in so strongly. I usually go to 2 lab meetings.

Fabian Theis

One lab meeting where they really need to learn and understand a deeper biological problem, and maybe understand the language of a medical setup or something like that. Typically, they're all computational, data science-type students, right? But then they go to the computational one. They get pushed on the method aspect of it, and thereby take up a whole bunch of problems that aren't yet precisely formulated in the biology lab, problems you can't directly put into a function.

Because they're method-y and quantitative, they can put this into a metric or whatever that then turns into a model and a paper. I think this is how we've been doing things for maybe 8 years or so, this type of school. A whole bunch of papers came out of it where I learned about systems I had no idea about before. People would approach me and ask, “Could we do something like this?” Then I’d learn something about the lung or the brain that I had no idea about.

I’d say, “Oh, hey, cool data. I think our model types could fit. Let’s build a project around it.” Those students became the experts in my lab on that detailed biological topic, together with a partner, and then we drove it forward. Nowadays, this also extends across data types. Early on, a lot of things were just around RNA, but since then we’ve had a very nice paper in Science last year on single-cell proteomics. We’ve also been extending things to spatial observations. There are all these additional modalities and things you can measure, and interesting questions come up in those domains where these assays work very well.

Speaker 1

Yeah, my natural inclination is to gather cross-domain stuff. I think it’s often ripe for the generation of really good and interesting ideas. As a follow-up, you’ve been doing this for 8 years now, I guess. What kinds of longer-term outcome benefits have you seen from this?

Fabian Theis

I think one thing that got students to join in initially is that, although it sounds like more work—you need to learn two things and go to two lab meetings—students in Germany, and Europe in general, typically do a master’s before they go into a PhD. So, not just a bachelor’s as in the U.S.; you do 1 or 2 more years of a master’s. They know a little bit about science, but they don’t exactly know what interests them. With this kind of combination, they can sample a bit because, in this grad school, they get different proposals. They can explore what they’re interested in domain-wise, and they can also play around with the method side.

I think trying out different things turned the students into very good data analysts, but also modeling people. The areas they went into downstream were equally diverse. Some went into pharma in their biomedical domain, some stayed in research, some went in a startup direction, and some went into very pure AI-type work. NVIDIA hired 2 of my people in 1 month just a few months ago, going very much into the computational aspect and also a bit of the biology part that NVIDIA is now building up. There are similar things happening at other big companies, so I think it gives them an interesting profile.

Nowadays, when you get interviewed, it’s a good idea to say, “I didn’t only do this fancy model that improved maybe 2% in a NeurIPS paper-type of thing. I also had the real, more complex, deeper application that I had to help find as a use case.”

Speaker 1

There’s been a movement in agentic AI. Several guests we’ve had, and a blog post we’ve published, have discussed how wet-lab scientists have started basically becoming computational thanks to agentic AI. I don’t know if this is—As I’m curious how this evolves, as agentic AI enables any scientist to become their own computational scientist, what do you think the evolution of this co-advising strategy is? And what do you think the evolution of integration between wet-lab biologists and computational teams will be? I’ve heard several famous CEOs say things like, “Our strength is integration between computational and wet-lab teams.” I’m curious how you think that evolves, and how you set up a culture to take advantage of these new technologies.

Fabian Theis

Let me keep the culture part out for a moment because I think it’s a hard one to answer, but a very good question. First, let me talk about the very cool point you asked about: where these things happen with deep integration. One of the most exciting frontiers we currently face, and an opportunity we have, is that we can really start guiding the experimentation. Before, we built these human cell atlases and had the mapping aspect. Then we talked about the world-model prediction problem. So from mapping, we went to prediction, but now we can go to actually steering the next experiment.

This has always been the scientific method: putting our hypothesis in the loop and then doing something with it. But quite frankly, very often papers end with some model, maybe a concept figure, maybe a little validation. Then you typically start the next project. Of course, you learn a bit, but it’s not really a continual-learning type of thing. Now I think we can actually loop back more and more. This is happening very much in molecule design or material design, where the lab-in-the-loop is really working out.

Even though some big pharma companies have been putting this out as a general big theme, there aren’t many examples yet where people really do multiple loops of integrating an experiment and a computational model, then going back—whether that’s 2 people or 1. This integration is hard to set up, partly because of modeling. Once you have a model, deciding what the optimal next question is not trivial.

We brought out a new thing, which we call Lab Compass, that should be on bioRxiv today or tomorrow. It’s an inverse generative model that allows you, once you have a forward world model or whatever, to figure out what you need to do to reach a certain state. It’s super exciting for us, and a big part of the work was not just the model but the work with experimental people. In this case, a good friend and colleague from the University of Cambridge was working on hematopoiesis and had a rapid-cycle system. We set up 3 or 4 lab-in-the-loop cycles where we iteratively improved a model.

This is a really hard thing, and it gets into your second question, Brandon: how do you bring up a culture where, once your computational person or model or whatever predicts something, you can convince experimental people to put their lab time in? These experiments often take some time, so they have to buy in and actually measure some of these follow-ups. Sometimes this works a bit better with molecules, because the stakes aren’t as high. But if you say, “You need to do this new cell line; you need to add these very strange things,” people might ask, “Do you really want to do this? Shouldn’t we maybe use a bit of our gut feeling?” Then these intermediate solutions come up.

I think setting this up is far from trivial. That needs culture, and it might be the same person doing it. A lot of people start throwing around robotics and so on as well, but I think that’s a tad too early because our assay cycle times are still a bit on the long side. I do think this will come, and obviously the ultimate vision is that we want to RL everything. We want to do RL in this loop as well. It’s a bit out there, but I think we’re slowly getting there.

Speaker 1

At the moment it’s more maybe active learning. Much like we talked about with Lila, that’s their core thesis: basically, the lab is part of the RL environment.

Fabian Theis

Mm-hmm. Yeah, no, that’s great.

Speaker 1

Fabian, it is late at night for you now. I really appreciate you taking the time out of your evening to talk to us. I look forward to watching your research—and when I say you, I mean your lab and colleagues, and you as well. I really look forward to watching this progress and keeping careful track of the things we talked about today.

Fabian Theis

Yeah, thanks so much, RJ, Brandon—

Speaker 1

Pleasure.

Fabian Theis

—for having me. I think these links are important, looking beyond what you do in your own smaller disciplines, and these discussions help me a lot.

I really enjoyed the discussion. Had a lot of fun. Thanks.

Speaker 1

Great. Thanks. Take care.

Fabian Theis

Thank you.